Instil Bio Inc. (TIL NASDAQ) stock market data APIs
$14.6996
-0.07(-0.5%)
as of May 16, 2025
Try our APIs with
free plan!
Instil Bio Inc. Financial Data Overview
Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. Its lead products candidate is AXN-2510/IMM2510 that is in Phase 1b/2 clinical trial for the treatment of patients with chemotherapy in patients with advanced/metastatic non-small cell lung cancer. The company also conducts a Phase 1 open label trial in China for AXN-2510/IMM2510 as monotherapy in patients with advanced solid tumors, including triple-negative breast cancer, squamous non-small cell lung cancer, hepatocellular carcinoma, renal cell carcinoma, and rare solid tumors, such as soft tissue sarcomas and thymic cancer. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.
Prev. Close
14.6996
Open
14.6323
High
15.0291
Low
14.2195
52 wk Range
9.62-92
Market Cap
95 972 K
Shares Outstanding
6 559 K
EPS
-1.32
Beta
1.795
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Instil Bio Inc. data using free add-ons & libraries
Get Instil Bio Inc. Fundamental Data
Instil Bio Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -56 348 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-08
- EPS/Forecast: -2.23
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Instil Bio Inc. News
New
Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
Enrollment of 1L NSCLC patients in China trial of AXN-2510/IMM2510 in combination with chemotherapy is ongoing with initial clinical data by ImmuneOnco expected in 2H 2025 Initiation of U.S. clinical...
Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Clinical data for AXN-2510/IMM2510 monotherapy in relapsed/refractory NSCLC in China by ImmuneOnco, as well as additional safety data in other solid tumors, anticipated in 1H 2025 Enrollment of 1L NS...
2 Stocks Up Over 700% in 2024 That Could Soar Even Further
Investors looking for stocks that can provide dramatic gains found what they were looking for with a pair of cancer drug developers. From the end of 2023 through the closing bell on Sept. 23, shares o...
Here's Why Everyone's Talking About Summit Therapeutics
September has been an exciting time for investors with their fingers on the pulse of cancer drug development. In a nutshell, it looks like the world's top-selling cancer therapy could have a serious c...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
